A molecule in late-stage clinical trial
ManRos Therapeutics owns a molecule which has reached a late-stage clinical trial.
The probability for a molecule to become a drug increases at each stage of development.
Cystic Fibrosis (CF)
After a promising Phase 2 trial on Roscovitine
ManRos Therapeutics develops Seliciclib (Roscovitine) for its stimulatory effects of bactericidal activity in alveolar macrophages (which is reduced in macrophages of CF patients, explaining chronic infections, particularly by Pseudomonas aeruginosa). Thanks to a public funding (PHRC, ‘Programme Hospitalier de Recherche Clinique’) and the support from the Association ‘Vaincre la Mucoviscidose’, ManRos Therapeutics, in collaboration with the Center for Clinical Investigation from the CHRU of Brest, received approval from the French Health Authority (ANSM) to conduct a clinical study to evaluate the safety and efficacy of Seliciclib (Roscovitine) in P. aeruginosa infected CF patients (13 hospitals, 36 patients, placebo-controlled, double-blind). The trial was launched in April 2016.
Refocusing research activities on a second-generation molecule
The recent clinical study conducted on Roscovitine, as a therapeutic indication of cystic fibrosis, has provided ManRos with real expertise in this area of research and development. Despite excellent safety results, efficacy attests to more mixed results, leading to a refocusing of research on a patentable molecule derived from roscovitine.
Its action, combined with a molecule already present on the market, would offer a potentiator effect, by increasing the functionality of the chloride channels. In the coming months, ManRos’ main challenge will be optimizing this new “drug candidate.”